Verdence Capital Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Verdence Capital Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-834	Closed	-$6.77K	–	560
2023 Q1	$6.77K	Hold	834	–	–	﹤0.01%	536
2022 Q4	$9.88K	Hold	834	–	–	﹤0.01%	494
2022 Q3	$12K	Hold	834	–	–	﹤0.01%	516
2022 Q2	$29K	Hold	834	–	–	﹤0.01%	507
2022 Q1	$33K	Sell	834 -1,214	-59%	-$52.1K	﹤0.01%	508
2021 Q4	$87K	Hold	2,048	–	–	0.01%	496
2021 Q3	$139K	Hold	2,048	–	–	0.02%	481
2021 Q2	$158K	Buy	2,048 +1,214	+146%	+$73.9K	0.02%	467
2021 Q1	$55K	Hold	834	–	–	0.01%	431
2020 Q4	$28K	Sell	834 -429	-34%	-$19.1K	0.01%	408
2020 Q3	$69K	Buy	+1,263	New	+$74.9K	0.02%	361

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Verdence Capital Advisors's DMK Position: Q2 2023 in Review

Verdence Capital Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 834 shares — an estimated $6.77K sold.

Verdence Capital Advisors first reported a position in DMK in Q3 2020 and held it in 11 quarters. The position peaked at $158K in Q2 2021. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Verdence Capital Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Verdence Capital Advisors sold 834 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $6.77K.
Verdence Capital Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2020 and held it in 11 quarters.
Verdence Capital Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $158K in Q2 2021.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Verdence Capital Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.